PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.12
Positive D/E while AGEN shows negative equity. John Neff would examine our competitive advantages in a challenging market.
0.76
Net debt while AGEN maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
-7.24
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
1.25
Current ratio below 50% of AGEN's 4.70. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.